`
`
`
`Paper No. ___
`
`Date Filed: Jan. 31, 2017
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`AMERIGEN PHARMACEUTICALS LIMITED and
`ARGENTUM PHARMACEUTICALS LLC
`
`Petitioners
`
`v.
`
`JANSSEN ONCOLOGY, INC.
`Patent Owner
`________________
`
`Case IPR2016-002861
`Patent No. 8,822,438 B2
`________________
`
`PATENT OWNER’S IDENTIFICATION OF NEW ARGUMENTS AND
`EVIDENCE IN PETITIONERS’ REPLY
`
`
`
`
`1 Case IPR2016-01317 has been joined with this proceeding.
`
`
`
`IPR2016-00286
`U.S. Patent 8,822,438
`
`
`
`
`Pursuant to the Board’s January 26, 2017 Order (Paper 68), Patent Owner
`
`Janssen Oncology, Inc. hereby submits an itemized list of what Patent Owner
`
`considers to be new arguments and evidence raised in Petitioners’ Reply, including
`
`paragraphs of the declarations of Drs. Ratain (Ex. 1091) and Dorin (Ex. 1093), as
`
`specifically identified below.
`
`1. New Argument and Evidence Regarding Motivation to Combine based
`on “Combined Congenital CYP 17 Deficiency”
`
`a. Pet. Reply, p. 4, l. 13 - p. 5, l. 3
`
`b. Pet. Reply, p. 10, l. 20 - p. 11, l. 5
`
`c. Ex. 1093 ¶¶ 15-19, 34-35, 61, 66
`
`2. New Arguments and Evidence Regarding Motivation to Combine Based
`on Adrenal Insufficiency, Concurrent Stress, or Adrenal Crisis
`
`a. Pet. Reply, p. 3, l. 20 - p. 4, l. 3
`
`b. Pet. Reply, p. 7, ll. 12-16
`
`c. Pet. Reply, p. 8, l. 7 - p. 9, l. 9
`
`d. Pet. Reply, p. 12, ll. 4-8
`
`e. Ex. 1091 ¶¶ 30, 35, 39; Ex. 1093 ¶¶ 20-24, 31-32, 36, 47-49, 53-54, 56,
`
`59-60, 62, 69
`
`3. New Argument Regarding Prednisone’s Safety Profile
`
`a. Pet. Reply, p. 10, ll. 5-13
`
`b. Ex. 1093 ¶ 30
`
`
`
`1
`
`
`
`IPR2016-00286
`U.S. Patent 8,822,438
`
`4. New Argument Regarding Glucocorticoids as Effective Anti-Cancer
`Agents
`
`a. Pet. Reply, p. 12, ll. 15-17
`
`b. Pet. Reply, p. 14, FN4
`
`c. Pet. Reply, p. 15, ll. 1-10
`
`d. Pet. Reply, p. 16, ll. 1-8
`
`e. Pet. Reply, p. 17, l. 5 - p. 18, l. 17
`
`f. Ex. 1091 ¶¶ 42-47, 54, 59-61, 63
`
`
`
`
`
`
`
`Dated: January 31, 2017
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin (Reg. No. 28,598)
`delderkin@akingump.com
`Barbara L. Mullin (Reg. No. 38,250)
`bmullin@akingump.com
`Ruben H. Munoz (Reg. No. 66,998)
`rmunoz@akingump.com
`AKIN GUMP STRAUSS HAUER &
`FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel: (215) 965-1200
`Fax: (215) 965-1210
`
`David T. Pritikin (pro hac vice)
`Bindu Donovan (pro hac vice)
`Paul J. Zegger (Reg. No. 33,821)
`Todd L. Krause (Reg. No. 48,860)
`
`2
`
`
`
`
`
`
`IPR2016-00286
`U.S. Patent 8,822,438
`
`
`
`
`
`
`
`S. Isaac Olson (pro hac vice)
`Alyssa B. Monsen (pro hac vice)
`SIDLEY AUSTIN LLP
`787 Seventh Avenue
`New York, NY 10019
`Tel.: (212) 839-5300
`Fax: (212) 839-5599
`ZytigaIPRTeam@sidley.com
`Counsel for Patent Owner
`
`
`
`3
`
`
`
`IPR2016-00286
`U.S. Patent 8,822,438
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Identification of New Arguments and Evidence in Petitioner’s Reply was
`
`served on counsel of record on January 31, 2017 by filing this document through
`
`the End-to-End System, as well as delivering a copy via electronic mail to counsel
`
`of record for the Petitioner and Patent Co-Owner at the following addresses:
`
`William Hare - bill@miplaw.com
`Gabriela Materassi - materassi@miplaw.com
`
`Teresa Stanek Rea - TRea@Crowell.com
`Shannon M. Lentz - SLentz@Crowell.com
`
`Anthony C. Tridico - anthony.tridico@finnegan.com
`Jennifer H. Roscetti - jennifer.roscetti@finnegan.com
`
`
`
`
`
`Date: Jan. 31, 2017
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`4
`
`